Company news
Level Bio Ab (NGM:LEVBIO) news
Level Bio Ab news releases on 6ix. Latest, Apr 23, 2026: LEVBIO: 15% sales growth and CyberGene divestment signal a strategic focus on diagnostics distribution
Press releases & updates
LEVBIO: 15% sales growth and CyberGene divestment signal a strategic focus on diagnostics distribution
April 23, 2026
LEVBIO: 29% sales growth and improved results, but future revenue to decline after CyberGene sale
February 19, 2026
LEVBIO: Q3 2025 saw 5% revenue growth, higher margins, and improved cash flow amid Nordic expansion
October 23, 2025
LEVBIO: Platform upgrades, Q4 pilot, and lab partnerships drive ongoing business development
August 21, 2025
LEVBIO: Nordic market growth surged 44% year-over-year, fueled by rebranding and tech advances
April 24, 2025
LEVBIO: Improved margins and reduced losses signal a turnaround, but liquidity remains a key risk
February 20, 2025
LEVBIO: Flat sales but improved results and cash flow signal operational progress and future growth
October 24, 2024
LEVBIO: Q2 sales grew 10% year-over-year, with H2 growth expected from new products
August 22, 2024